(MedPage Today) — Some heart failure patients had arguably better outcomes after simultaneous initiation of an SGLT2 inhibitor plus a mineralocorticoid receptor antagonist (MRA) in the SOGALDI-PEF trial, but safety markers set off alarms.
In…
Source link : https://www.medpagetoday.com/cardiology/chf/116696
Author :
Publish date : 2025-07-28 18:04:00
Copyright for syndicated content belongs to the linked Source.
